Context Therapeutics/$CNTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- Ticker
- $CNTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- Philadelphia, United States
- Website
- www.contexttherapeutics.com
CNTX Metrics
BasicAdvanced
$20M
-
-$0.46
1.80
-
Price and volume
Market cap
$20M
Beta
1.8
52-week high
$3.62
52-week low
$0.18
Average daily volume
1.3M
Financial strength
Current ratio
6.593
Quick ratio
6.255
Long term debt to equity
0.001
Total debt to equity
0.007
Profitability
EBITDA (TTM)
-46.054
Management effectiveness
Return on assets (TTM)
-49.75%
Return on equity (TTM)
-84.26%
Valuation
Price to book
0.64
Price to tangible book (TTM)
0.64
Price to free cash flow (TTM)
-0.484
Free cash flow yield (TTM)
-206.75%
Free cash flow per share (TTM)
-0.447
Growth
Earnings per share change (TTM)
60.21%
3-year earnings per share growth (CAGR)
-29.21%
What the Analysts think about CNTX
Analyst ratings (Buy, Hold, Sell) for Context Therapeutics stock.
Analyst projections of the future price of Context Therapeutics stock.
CNTX Financial Performance
Revenues and expenses
CNTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.